[8-K] Evoke Pharma, Inc. Reports Material Event

Rhea-AI Filing Summary

Gilat Satellite Networks Ltd. (NASDAQ/TASE: GILT) filed a Form 6-K that includes a 9 July 2025 press release announcing that its Commercial Division has secured more than US$22 million in purchase orders from several Tier-One satellite operators. The equipment and services will be delivered over the next 12 months and span GEO, MEO and LEO Very-High-Throughput Satellite (VHTS) constellations. Management highlights particular momentum in the rapidly expanding In-Flight Connectivity (IFC) market.

According to President Ron Levin, the awards reinforce customer confidence in Gilat’s ground-segment infrastructure, system management, mobility solutions and broadband products. The company positions the wins as evidence of its ability to support large-scale, high-performance deployments across multiple orbital architectures, an important differentiator as satellite operators roll out multi-orbit networks.

Key takeaways

• Orders total >$22 million, scheduled for fulfillment within 12 months.
• Customers are unnamed but described as “leading satellite operators” worldwide.
• Applications focus on IFC, mobility, broadband and enterprise connectivity.
• The awards leverage Gilat’s cloud-based platform, modems, terminals, SOTM antennas, SSPAs/BUCs and network management software.

The disclosure does not provide revenue guidance or margin details, but the size and Tier-One nature of the orders suggest incremental top-line growth and further penetration in high-growth IFC and multi-orbit markets. No financial tables or earnings data were included.

Positive

• Secured over US$22 million in orders from Tier-One satellite operators, enhancing backlog for the next 12 months.
• Demonstrates traction across GEO, MEO and LEO VHTS constellations, underpinning Gilat’s multi-orbit strategy.
• Strengthening presence in the fast-growing In-Flight Connectivity (IFC) segment, a key driver of future revenue.

Negative

• None.

Insights

Satellite Industry Specialist

TL;DR: New US$22 m orders strengthen Gilat’s foothold in multi-orbit & IFC markets; positive signal for near-term revenue.

The purchase orders confirm commercial traction for Gilat’s multi-orbit ground-segment portfolio at a time when GEO, MEO and LEO operators are scaling capacity. Although the absolute value is modest versus large satellite projects, it likely represents a meaningful single-contract contribution for Gilat and may translate into higher utilisation at its manufacturing units over the coming year. Continued wins in IFC—one of the fastest-growing satellite segments—position the company well as airlines upgrade connectivity offerings. The announcement does not disclose margins, customer identities or competitive context, so the exact profitability impact is unknown, but the Tier-One reference implies repeat business from blue-chip operators, enhancing credibility.

Equity Research Analyst

TL;DR: Contract awards >US$22 m are incrementally positive; limited detail keeps overall impact moderate.

At >US$22 m, the orders could add a few percentage points to annual revenue, depending on Gilat’s run-rate, and support backlog visibility through FY-2026. Delivery within 12 months accelerates recognition relative to multi-year government deals. The lack of disclosed gross margin prevents assessment of EPS impact, yet Tier-One pedigree typically yields repeat and larger follow-on contracts. No negative operational issues were revealed, and the filing maintains a neutral tone apart from standard forward-looking statements.

0001403708false00014037082025-07-092025-07-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 09, 2025

EVOKE PHARMA, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-36075	20-8447886
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
420 Stevens Avenue, Suite 230
Solana Beach, California				92075
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 858 345-1494

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		EVOK		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On July 9, 2025, Evoke Pharma, Inc. (“Evoke” or the “Company”) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for a U.S. patent application covering the use of GIMOTI® in patients with moderate to severe symptoms of gastroparesis. The allowed application is a continuation of U.S. Patent No. 11,517,545, and further expands Evoke’s intellectual property estate around intranasal metoclopramide. Upon issuance, the patent will be expected to expire in December 2036 and the Company intends to list the patent in the FDA’s Orange Book, extending market exclusivity for GIMOTI® beyond other existing patents.

Safe Harbor Statement

Evoke cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Company’s current beliefs and expectations. These forward-looking statements include statements regarding: the timing of the USPTO granting the patent application and the Company’s plans to list the patent in the Orange Book and pursue additional claims directed to treatments for certain patient populations; and the additional value of the GIMOTI franchise as a result of the patent application. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke’s ability to obtain and maintain intellectual property protection for GIMOTI and the FDA ultimately updating the Orange Book listing with the new patent; Evoke and EVERSANA may not be able to successfully drive market demand for GIMOTI; the results of market research studies may not predict acceptance by patients, healthcare providers or payors; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Evoke Pharma, Inc.
Date:	July 9, 2025	By:	/s/ Matthew J. D'Onofrio
			Name: Maatthew J. D'Onofrio Title: Chief Executive Officer and Director

FAQ

What did Gilat Satellite Networks (GILT) announce on July 9, 2025?

Gilat reported receiving over US$22 million in orders from leading satellite operators, disclosed via Form 6-K.

How soon will the new GILT orders be delivered?

The equipment and services are scheduled for delivery within the next 12 months.

Which markets are driving Gilat’s new orders?

The orders target GEO, MEO, and LEO VHTS constellations with strong demand in the In-Flight Connectivity (IFC) market.

Did the filing disclose the names of the satellite operators?

No. The press release refers only to “Tier-One satellite operators” without naming them.

Is there any financial guidance included in the 6-K?

The filing does not provide revenue, margin or EPS guidance; it focuses solely on the new orders.